Our contributions to EHA 2026 in Stockholm
At a glance
The team contributed to six abstracts at this year's EHA Congress, held in Stockholm, spanning lymphoma and myeloma/MGUS research with one oral presentation.
We're thrilled to share that our team contributed to six abstracts at this year's EHA Congress, held in Stockholm. The contributions span both lymphoma and myeloma/MGUS research, including one oral presentation, and reflect our ongoing work in haematological malignancies. A big thank you to the entire team involved in these projects.
Lymphoma contributions: Safety data and initial pooled efficacy data from the Nordic Lymphoma Group Phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma — R-POLA-mini-CHP vs. R-mini-CHOP (oral presentation, abstract S238); infection rates in patients treated with CAR-T versus autologous stem cell transplant for relapsed/refractory large B-cell lymphoma and in the general population: a Swedish population-based study (poster, abstract PS2085); treatment for malignant lymphomas and risk of therapy-related myeloid neoplasms overall and with high-risk features (poster, abstract PS2096).
Myeloma and MGUS contributions: Significant improvements in survival outcomes in smouldering multiple myeloma: a population-based study (poster, abstract PF801); patterns of MGUS in men and women participating in the screened population-based iStopMM study (poster, abstract PS1900); antidiabetic medication use and monoclonal gammopathy of undetermined significance: associations with prevalence and M-protein trajectories in the iStopMM study (poster, abstract PF835).